Article PDF first page preview

First page of Treatment effects of panretinal photocoagulation or combined anti-vascular endothelial growth factor therapy for proliferative diabetic retinopathy on the risks of diabetic macular edema and vitreous hemorrhage

Introduction: This study evaluated the effect of panretinal photocoagulation (PRP) or combined both anti-VEGF therapy and PRP in proliferative diabetic retinopathy (PDR) on the risk of diabetic macular edema (DME) or vitreous hemorrhage (VH) and compared functional, anatomical outcomes and additional treatments in the two groups. Methods: This retrospective analysis involves patients treated for PDR with either PRP alone or in combination with three consecutive anti-VEGF injections, followed for at least 12 months. Treatment effects and other factors associated with the risk of first DME and VH were assessed. Results: We identified 95 eyes from 69 patients (combined group: 37 eyes from 25 patients; PRP group: 58 eyes from 44 patients). At one year the cumulative incidences of the first DME and VH were 8% and 19% (combined group), and 31% and 19% (PRP group), respectively. Combined treatment reduced the risk of first DME after adjusting for age, HbA1c level, PDR severity, and baseline CRT (csHR: 0.211, 95% CI: 0.064–0.700, p=0.011). Increased DME risks correlated with poor blood sugar control (HbA1c ≥8.4%), thicker baseline CRT in non-high-risk PDR, and baseline CRT <232μm in high-risk PDR. The risk of first VH decreased with age (csHR: 0.966, 95% CI: 0.933–0.999, p=0.045). The combined group exhibited superior best-corrected visual acuity at the third and twelfth months. The combined group were less likely to require additional treatment within one year (adjusted OR: 0.254, 95% CI: 0.088–0.739, p=0.011). Conclusion: Combining anti-VEGF agents with PRP effectively reduced the risk of DME, yielding improved visual outcomes and fewer additional treatments within one year.

Journal Section:
Research Article
This content is only available via PDF.
The Author(s). Published by S. Karger AG, Basel
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License .
Attribution-NonCommercial